kaonavi
4435
D. Western Therapeutics Institute
4576
Itamiarts
168A
Nakayo
6715
Allied Telesis Holdings KK
6835
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.46%173.28B | 17.86%166.16B | 9.00%601.12B | 8.84%157.64B | 11.29%159.76B | 3.50%142.75B | 12.60%140.98B | 12.34%551.5B | 10.75%144.84B | 5.65%143.54B |
Cost of revenue | 8.47%143.2B | 15.96%139.35B | 7.11%512.25B | 7.88%138.64B | 9.47%132.02B | 1.58%121.41B | 9.63%120.18B | 8.17%478.26B | 5.06%128.52B | 4.64%120.6B |
Gross profit | 8.44%30.08B | 28.87%26.81B | 21.34%88.88B | 16.41%19B | 20.89%27.74B | 15.95%21.34B | 33.52%20.8B | 50.14%73.25B | 93.32%16.32B | 11.29%22.94B |
Operating expense | 13.60%15.36B | 16.04%15.13B | 7.15%54.13B | -0.19%14.37B | 9.74%13.52B | 6.13%13.2B | 14.75%13.04B | 10.16%50.52B | 18.20%14.4B | 8.97%12.32B |
Operating profit | 3.53%14.72B | 50.42%11.67B | 52.87%34.75B | 140.64%4.63B | 33.82%14.22B | 36.42%8.14B | 84.13%7.76B | 675.31%22.73B | 151.49%1.92B | 14.11%10.63B |
Net non-operating interest income (expenses) | -6.87%-809M | -13.84%-806M | -7.91%-3.01B | -12.43%-796M | -9.39%-757M | -5.91%-753M | -3.81%-708M | 3.86%-2.79B | 0.42%-708M | 1.98%-692M |
Non-operating interest income | 650.00%75M | 155.56%23M | 80.77%47M | 128.57%16M | 66.67%10M | 71.43%12M | 50.00%9M | 18.18%26M | 0.00%7M | 50.00%6M |
Non-operating interest expense | 15.25%884M | 15.62%829M | 8.58%3.06B | 13.57%812M | 9.89%767M | 6.55%765M | 4.22%717M | -3.69%2.82B | -0.42%715M | -1.69%698M |
Net investment income | 16.72%691M | 65.92%1.19B | 6.49%1.38B | -53.13%30M | 8.42%592M | 127.78%41M | 7.35%716M | 10.59%1.3B | 814.29%64M | 9.20%546M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -79.87%32M | 0 | 5.69%1.75B | 86.63%1.56B | -73.46%159M | -97.47%7M | 127.87%17M | -45.86%1.65B | -36.47%838M | 383.06%599M |
Income from associates and other participating interests | -61.91%550M | -48.23%453M | 13.61%3B | -66.04%290M | 118.13%1.44B | -32.58%387M | 59.96%875M | -19.04%2.64B | 8.38%854M | -38.99%662M |
Special income (charges) | 92.62%-24M | 460.98%2.17B | -864.09%-4.75B | -1,320.39%-1.86B | -256.25%-325M | -3,022.77%-2.95B | 141.88%387M | 630.77%621M | 13.43%152M | -38.64%208M |
Less:Restructuring and mergern&acquisition | --0 | ---1.98B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Impairment of capital assets | ---- | --26M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Other special charges | -95.40%11M | 46.65%-215M | 186.17%2.98B | 111.64%332M | 203.91%239M | 1,515.08%2.82B | -122.65%-403M | -87.19%-3.46B | -73.22%-2.85B | 50.32%-230M |
Less:Write off | ---- | ---- | -38.04%1.76B | -43.61%1.52B | 290.91%86M | 38.78%136M | -23.81%16M | 44.48%2.84B | 78.52%2.7B | -82.26%22M |
Other non-operating income (expenses) | -18.92%90M | -48.16%254M | -42.55%1.43B | -44.07%486M | -78.45%111M | -37.45%344M | -12.03%490M | -71.30%2.49B | -67.48%869M | -63.14%515M |
Income before tax | -1.22%15.26B | 56.55%14.93B | 20.65%34.55B | 8.89%4.35B | 23.92%15.44B | -23.04%5.22B | 76.60%9.54B | 78.19%28.63B | 742.62%3.99B | 3.41%12.46B |
Income tax | -3.50%3.23B | 87.46%4.2B | 3.91%9.14B | 19.84%1.21B | -6.80%3.34B | 13.99%2.35B | 4.67%2.24B | 52.42%8.79B | 376.16%1.01B | -11.08%3.59B |
Net income | -0.59%12.03B | 47.09%10.73B | 28.07%25.41B | 5.22%3.14B | 36.33%12.1B | -39.19%2.87B | 123.77%7.3B | 92.62%19.84B | 255.48%2.99B | 10.70%8.88B |
Net income continuous operations | -0.59%12.03B | 47.07%10.73B | 28.06%25.41B | 5.19%3.14B | 36.33%12.1B | -39.20%2.87B | 123.80%7.3B | 92.63%19.84B | 255.90%2.99B | 10.70%8.88B |
Noncontrolling interests | 23.77%682M | 335.19%235M | 1.92%1.01B | 658.33%273M | -23.90%551M | -16.56%131M | -26.03%54M | 6.57%990M | 110.91%36M | -13.29%724M |
Net income attributable to the company | -1.76%11.35B | 44.93%10.5B | 29.44%24.4B | -2.75%2.87B | 41.66%11.55B | -39.96%2.74B | 127.27%7.24B | 101.17%18.85B | 152.35%2.95B | 13.49%8.15B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -1.76%11.35B | 44.93%10.5B | 29.44%24.4B | -2.75%2.87B | 41.66%11.55B | -39.96%2.74B | 127.27%7.24B | 101.17%18.85B | 152.35%2.95B | 13.49%8.15B |
Gross dividend payment | ||||||||||
Basic earnings per share | -1.63%57.8 | 44.87%53.4 | 29.42%124.13 | -2.80%14.59 | 41.66%58.76 | -40.00%13.92 | 127.25%36.86 | 101.28%95.91 | 152.69%15.01 | 13.52%41.48 |
Diluted earnings per share | -10.60%49.1 | 42.39%49.04 | 29.45%116.01 | -2.78%13.64 | 41.69%54.92 | -39.99%13.01 | 127.33%34.44 | 101.26%89.62 | 152.34%14.03 | 13.53%38.76 |
Dividend per share | 0 | 0 | 37.50%27.5 | 37.50%27.5 | 0 | 0 | 0 | 60.00%20 | 60.00%20 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |